Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): A multicentre, open-label, randomised, controlled phase II trial

Source: MDLinx, March 2019

In a phase 2, randomized, open-label trial, researchers investigated the therapeutic effectiveness of inhibiting mitogen-activated protein kinase pathway by adding kinase inhibitors trametinib or pazopanib to paclitaxel chemotherapy in patients with advanced wild-type BRAF (BRAF-wt) melanoma. A total of 38 patients were randomized to paclitaxel alone, 36 were treated with paclitaxel and trametinib, and 37 with paclitaxel and pazopanib. A maximum of six cycles of paclitaxel and once daily oral administration of 2 mg trametinib and 800 mg pazopanib until disease progression or unacceptable toxicity was administered. An improved progression-free survival and considerably increased objective response rate were achieved with the addition of trametinib to paclitaxel chemotherapy, while no effect was seen on overall survival.

read the original full article